Trial NCT02128230

View at ClinicalTrials.gov 
Org. Study IDs: 134668

Last trial update was posted on 2021-06-22

MeSH Interventions

BB 1101 Cisplatin Cyclophosphamide Dexamethasone Dexamethasone acetate Doxorubicin Etoposide Etoposide phosphate Lenalidomide Lenograstim Liposomal doxorubicin Melphalan Thalidomide

MeSH Conditions

Multiple Myeloma Neoplasms, Plasma Cell

Other Conditions


Stopping Reasons

Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.

Limitations And Caveats

The study was terminated early due to futility as determined by Amgen's Carfilzomib NASCR program in addition to low enrollment.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID